Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine in ALS
NCT03472950Phase 2Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Jun 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ranolazine in amyotrophic lateral sclerosis (ALS), sponsored by University of Kansas Medical Center. Started Jun 2018; status: completed.
02
Drugs
ranolazine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03472950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472950.